Therefore, IL-23 antagonists appear to have a therapeutic effect on psoriasis, and this selective blockade of IL-23 subunit may have greater efficacy than the blockade of the p40 subunit, common to IL-12 and IL-23. This evidence concerns the gene IL23A and psoriasis.